Empagliflozin Inhibits Cardiac Late Sodium Current by Ca/Calmodulin-Dependent Kinase II-Reference-Cited by-同舟云学术

Empagliflozin Inhibits Cardiac Late Sodium Current by Ca/Calmodulin-Dependent Kinase II

Published:2022-10-18 Issue:16 Volume:146 Page:1259-1261
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Mustroph Julian¹^ORCID,Baier Maria J.¹^ORCID,Pabel Steffen¹,Stehle Thea¹,Trum Maximilian¹^ORCID,Provaznik Zdenek²^ORCID,Mohler Peter J.³^ORCID,Musa Hassan³,Hund Thomas J.³^ORCID,Sossalla Samuel¹^ORCID,Maier Lars S.¹^ORCID,Wagner Stefan¹^ORCID

Affiliation:

1. Department of Internal Medicine II (J.M., M.J.B., S.P., T.S., M.T., S.S., L.S.M., S.W.), University Medical Center Regensburg, Germany.

2. Department of Cardiothoracic Surgery (Z.P.), University Medical Center Regensburg, Germany.

3. Davis Heart and Lung Research Institute, Ohio State University, Columbus (P.J.M., H.M., T.J.H.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference5 articles.

1. Philippaert K Kalyaanamoorthy S Fatehi M et al. The cardiac late sodium channel current is a molecular target for the sodium-glucose co-transporter 2 inhibitor empagliflozin. Circulation. 2021. Accessed May 21 2021. https://doi.org/10.1161/CIRCULATIONAHA.121.053350

2. Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels

3. Reactive Oxygen Species–Activated Ca/Calmodulin Kinase IIδ Is Required for Late I Na Augmentation Leading to Cellular Na and Ca Overload